Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
, linked to a radioisotope emitting ionizing radiation. During their preclinical development phase, these therapeutic agents are administered to tumor-bearing rodents undergoing longitudinal small-animal
-
. • Share concerns appropriately by avoiding direct confrontation in staff meetings: supporting in public, confronting in private. • Participate in RA selection and evaluation processes. • Role model
-
platform – creation of a domain-specific, constrained Large Language Model (LLM) and AI agents for use within an OMS; Model development and training; Integration of AI agents. Applicable legislation and
-
applications. This project key innovation lies in incorporating novel antivirulence compounds (agents that target bacterial quorum sensing rather than viability) into these scaffolds. By inhibiting pathogenic
-
intensive multi-cellular agent based models (ABMs) of Epstein–Barr Virus (EBV) and HIV-1 infection dynamics in human lymphoid tissue. This postdoctoral associate will collaborate with experimentalists
-
fungal infections. Emerging research is exploring radiometals conjugated with targeting molecules for in vivo imaging of infections via PET or SPECT. These agents can also be linked to therapeutics
-
fungal infections. Emerging research is exploring radiometals conjugated with targeting molecules for in vivo imaging of infections via PET or SPECT. These agents can also be linked to therapeutics
-
at adapting our blood-brain barrier model to predict the brain permeability of extracellular vesicles and therapeutic agents. It by the use of cell culture, automation, high content imaging, TEER and
-
. Mentor and project matches will be based upon your academic experience and professional interests. At the end of your internship you will be expected to prepare a slide presentation based on your
-
individual synovial membrane and osteochondral unit-on-chip models as well as a their combination in the joint-on-chip to test established and new disease modifying agents to validate their use in drug